Widely used kidney cancer drugs can't stop recurrence
Thursday, March 10, 2016 - 15:30
in Health & Medicine
Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study.